From all the variables evaluated in our study, the burst of CD4 THD cells was very significantly associated with patients with G2 profile (46.4% vs. 0%, p < 0.0001) and with patients treated with atezolizumab than with pembrolizumab or nivolumab (41.7% vs. 11.1% vs. 6.7% respectively, p = 0.005), and significantly associated with PD-L1 tumor expression < 5% (34.6% vs. 9.1%, p = 0.036). The gene discussed is CD274; the disease is neoplasm.